Company Information
NervGen Pharma was founded on January 2017. The company is based in Vancouver. The number of employees in NervGen Pharma is less than 50. Nervgen pharma is a medicine company dedicated to creating solutions for the treatment of nerve damage and neurodegenerative diseases.Funding & investors
NervGen Pharma has received 3 rounds of venture funding. The total funding amount is around $2.8M.Similar Companies [beta]
Venture Categories
Active Venture Investors
Venture Competitors
News
NervGen Pharma - Blog
- Embracing Your Support System After Brain Injury
- NervGen Hosting Panel Discussion with Leading Experts at the 2022 Annual Meeting of American Spinal Cord Injury Association (ASIA)
- NervGen Pharma Receives Approval to Proceed to the Final Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q1 2022 Results
- The Outdoor Diaries: Sit-Skiing After Spinal Cord Injury
- In Case I Forget – Support for Alzheimer’s Caregivers
- NervGen Pharma Appoints Craig Thompson to the Board of Directors
By Codi Darnell May 17, 2022 When you experience a brain injury, it can feel as though you’ve been picked up out of your life and deposited onto the sidelines. The life you were living – all your obligations and the daily tasks you completed – still exist, but you’ve been removed from the action. […]The post Embracing Your Support System After Brain Injury appeared first on Nervgen Pharma.
Panel discussion will focus on the successful translation of NervGen’s lead compound, NVG-291, from animals to humans Leading spinal cord injury experts on the panel include Drs. Jerry Silver, Monica Perez and James Guest NervGen will also present at the International Investment Forum Vancouver, Canada. May 16, 2022 – NervGen Pharma Corp. (TSX-V: NGEN; […]The post NervGen Hosting Panel Discussion with Leading Experts at the 2022 Annual Meeting of American Spinal Cord Injury Association (ASIA) appeared first on Nervgen Pharma.
Safety Review Committee approves proceeding to third and highest dose cohort in multiple ascending dose portion of clinical trial No serious or severe adverse events reported in second dose cohort with NVG-291 Successful completion of the second cohort establishes a clear pathway to selecting a dose for upcoming Phase 1b/2 clinical trials Vancouver, Canada. […]The post NervGen Pharma Receives Approval to Proceed to the Final Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q1 2022 Results appeared first on Nervgen Pharma.
Welcome to our blog series: The Outdoor Diaries. This series is about exploring the natural world from the perspective of people with chronic conditions and/or mobility issues. While the benefits of nature are for everybody, access to it isn’t always quite as simple. By Codi Darnell May 3, 2022 “Skiing and sunshine, what more do you […]The post The Outdoor Diaries: Sit-Skiing After Spinal Cord Injury appeared first on Nervgen Pharma.
By Codi Darnell April 19, 2022 “My vision for In Case I Forget, LLC is to remember for those who forget and to remind caregivers that they are not alone on this journey.” – Ty Lewis Navigating an Alzheimer’s disease diagnosis with a loved one and deciding on the best course of action when it […]The post In Case I Forget – Support for Alzheimer’s Caregivers appeared first on Nervgen Pharma.
30 years of industry experience from CEO of Nasdaq-listed biotech to Vice President, Marketing at Pfizer Experience on 16 development stage products, 15 commercial stage products and numerous pre-clinical assets, in both start-up and large pharmaceutical companies Vancouver, Canada. April 13, 2022 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a […]The post NervGen Pharma Appoints Craig Thompson to the Board of Directors appeared first on Nervgen Pharma.
Share:
